0001209191-20-049554.txt : 20200903
0001209191-20-049554.hdr.sgml : 20200903
20200903184131
ACCESSION NUMBER: 0001209191-20-049554
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200901
FILED AS OF DATE: 20200903
DATE AS OF CHANGE: 20200903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chaubey Alka
CENTRAL INDEX KEY: 0001821605
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38613
FILM NUMBER: 201160288
MAIL ADDRESS:
STREET 1: C/O BIONANO GENOMICS, INC.
STREET 2: 9540 TOWNE CENTRE DRIVE, SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bionano Genomics, Inc
CENTRAL INDEX KEY: 0001411690
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 261756290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9540 TOWNE CENTRE DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 888-7600
MAIL ADDRESS:
STREET 1: 9540 TOWNE CENTRE DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: BioNano Genomics, Inc
DATE OF NAME CHANGE: 20120703
FORMER COMPANY:
FORMER CONFORMED NAME: BioNanomatrix Inc
DATE OF NAME CHANGE: 20070906
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2020-09-01
2020-09-03
0
0001411690
Bionano Genomics, Inc
BNGO
0001821605
Chaubey Alka
C/O BIONANO GENOMICS, INC.
9540 TOWNE CENTRE DRIVE, SUITE 100
SAN DIEGO
CA
92121
0
1
0
0
Chief Medical Officer
Stock Option (Right to Buy)
0.56
2020-09-01
4
A
0
300000
0.00
A
2030-09-01
Common Stock
300000
300000
D
25% of the shares subject to the stock option vest and become exercisable on August 31, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan.
The Form 4 is being amended for the sole purpose to change a typographical error in the exercise price of derivative security in column 2 of Table II.
/s/ R. Erik Holmlin, Attorney-in-Fact
2020-09-03